| Revenue growth | FY26 revenue grew 18% YoY to ₹1,549cr; Q4 grew 30%. |
|---|---|
| Margins | FY26 Gross Margin 70%; EBITDA margin 29% (up 300bps YoY). |
| Demand visibility | Strong order book for NorUDCA; robust pipeline for European formulations. |
| Management confidence | High confidence in technology-driven growth and monetization of R&D investments. |
Growth
FY26 EBITDA rose 30% to ₹445cr; adjusted PAT grew 135% to ₹232cr. API revenue ₹985cr (+16%); Formulations ₹618cr (+30%).
Outlook
Focus on monetizing ADCs, biologics, and peptides. Commercializing Abraxane/Enzalutamide in FY28. Targeting 35% EBITDA margins long-term.
Risks
USFDA audit observations at Jadcherla facility; increased raw material prices; competition in Nilotinib generic market in FY28.
Earnings Call filed with BSE, NSE: SHILPAMED. Summary written with AI assistance from the document.
Shilpa Medicare Ltd: key numbers
- Share price
- ₹1,013.45
- Market cap
- ₹19,821 Cr
- Revenue (annual)
- ₹1,539 Cr
- Net profit (annual)
- ₹243.3 Cr
- P/E (TTM)
- 66.7×Sector 50.4×
- Promoter holding
- 40.13%+0.00% QoQ
- FII holding
- 11.39%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Shilpa Medicare Ltd
All →Shilpa Medicare Share Pledge
The company's promoters reported the release of encumbrance on 30,00,000 equity shares held by them. This reduction in pledged shares signals a change in promoter leverage.
Shilpa Medicare Other Announcement
Shilpa Medicare received a 'Crisil ESG 59' rating from CRISIL ESG Ratings for FY2026. This is a routine regulatory disclosure under Regulation 30 with no financial implications.
Shilpa Medicare Business Update
Shilpa Medicare reported a USFDA surveillance inspection at its Unit VII Analytical Services Division. The inspection resulted in one procedural observation with no material impact on operations.
Shilpa Medicare Regulatory Approval
Shilpa Medicare secured final CDSCO-SEC approval for OERIS™, a world-first extended-release ondansetron injection patented until 2039. Commercial launch in India is planned upon final marketing authorization.
Shilpa Medicare Annual General Meeting
Shilpa Medicare's 39th AGM held 11 September 2026 via VC. Resolutions covered financial statement adoption, ₹0.60/share dividend, and director re-appointment.
Shilpa Medicare Insolvency Petition
NCLT Ahmedabad admitted FTF Pharma, Shilpa Medicare's subsidiary, to CIRP over a ₹2.18 Crore debt. IRP appointed with moratorium; impact on parent unquantifiable.
- Value
- ₹2.18 Cr